EP4308227A1 - Inhibiteurs imidazopyridinyle de la kallicréine plasmatique - Google Patents

Inhibiteurs imidazopyridinyle de la kallicréine plasmatique

Info

Publication number
EP4308227A1
EP4308227A1 EP22714692.5A EP22714692A EP4308227A1 EP 4308227 A1 EP4308227 A1 EP 4308227A1 EP 22714692 A EP22714692 A EP 22714692A EP 4308227 A1 EP4308227 A1 EP 4308227A1
Authority
EP
European Patent Office
Prior art keywords
compound
pyridin
mmol
cyclopropylimidazo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22714692.5A
Other languages
German (de)
English (en)
Inventor
Nikolaos PAPAIOANNOU
Jeremy Mark Travins
Sarah Jocelyn FINK
John Mark Ellard
Alastair Rae
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of EP4308227A1 publication Critical patent/EP4308227A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • Plasma Kallikrein (PKa) is a serine protease zymogen in blood that is converted to its catalytically active form by coagulation factor XIIa, and contributes to the innate inflammatory response and intrinsic cascade of blood coagulation.
  • C1 inhibitor C1 inhibitor
  • PKa-mediated cleavage of high-molecular weight kininogen generates the potent vasodilator and pro-inflammatory nonapeptide bradykinin (BK), which activates the bradykinin 2 receptor.
  • BK bradykinin
  • Subsequent cleavage of BK by carboxypeptidases generates des-Arg9-BK, which activates the B1 receptor.
  • PKa is also associated with a number of disorders, such as hereditary angioedema (HAE), an autosomal dominant disease characterized by painful, unpredictable, recurrent attacks of inflammation affecting the hands, feet, face, abdomen, urogenital tract, and the larynx. Prevalence for HAE is uncertain but is estimated to be approximately 1 case per 50,000 persons without known differences among ethnic groups.
  • HAE hereditary angioedema
  • HAE is caused by deficient (Type I) or dysfunctional (Type II) levels of C1-INH, which inhibits PKa, bradykinin, and other serine proteases in the blood.
  • Individuals with hereditary angioedema (HAE) are deficient in C1-INH and consequently undergo excessive bradykinin generation, which in turn cause painful, debilitating, and potentially fatal swelling attacks. If left untreated, HAE can result in a mortality rate as high as 40% primarily due to upper airway obstruction.
  • the present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein each of Cy A , Cy B , L, L’, R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 is defined and described in classes and subclasses herein, both singly and in combination.
  • the present invention provides compounds of Formulae (I)-(VI-c), as defined and described in classes and subclasses herein. [0006] In some embodiments, the present invention also provides methods of using compounds of Formulae (I)-(VI-c). [0007]
  • compounds of the present disclosure have therapeutic activity and adequate levels of bioavailability and/or adequate half-life for use as a therapeutic. III. DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS A. Definitions [0008] Compounds of this invention include those described generally above, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated.
  • aliphatic or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “carbocyclyl,” “cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule.
  • aliphatic groups contain 1-6 aliphatic carbon atoms.
  • aliphatic groups contain 1-5 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms.
  • “cycloaliphatic” refers to a monocyclic C3-C7 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule.
  • Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
  • heteroatom means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4- dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl)).
  • unsaturated as used herein, means that a moiety has one or more units of unsaturation.
  • alkylene refers to a bivalent alkyl group.
  • alkylene chain is a polymethylene group, i.e., -(CH2)n-, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3.
  • a substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
  • halogen means F, Cl, Br, or I.
  • aryl refers to monocyclic and bicyclic ring systems having a total of five to 10 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains three to seven ring members.
  • the term “aryl” may be used interchangeably with the term “aryl ring”.
  • an 8-10 membered bicyclic aryl group is an optionally substituted naphthyl ring.
  • “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents.
  • aryl is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.
  • heteroaryl and “heteroar-” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 ⁇ electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms.
  • Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl.
  • heteroaryl and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring (or in the case of a bivalent fused heteroarylene ring system, at least one radical or point of attachment is on a heteroaromatic ring).
  • Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one.
  • a heteroaryl group may be mono- or bicyclic.
  • the term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted.
  • the terms “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above.
  • nitrogen includes a substituted nitrogen.
  • the nitrogen in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or + NR (as in N-substituted pyrrolidinyl).
  • a heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
  • saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl.
  • heterocyclyl refers to groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the heterocyclyl ring.
  • a heterocyclyl group may be mono- or bicyclic.
  • heterocyclylalkyl refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
  • the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond.
  • the term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
  • the suffix “-ene” is used to describe a bivalent group.
  • any of the terms above can be modified with the suffix “-ene” to describe a bivalent version of that moiety.
  • a bivalent carbocycle is “carbocycylene”
  • a bivalent aryl ring is “arylene”
  • a bivalent benzene ring is “phenylene”
  • a bivalent heterocycle is “heterocyclylene”
  • a bivalent heteroaryl ring is “heteroarylene”
  • a bivalent alkyl chain is “alkylene”
  • a bivalent alkenyl chain is “alkenylene”
  • a bivalent alkynyl chain is “alkynylene”
  • compounds of the invention may, when specified, contain “optionally substituted” moieties.
  • substituted whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. “Substituted” applies to one or more hydrogens that are either explicit or implicit from the structure (e.g., refers to at least ; and refers to at least , , ).
  • substituents may, unless otherwise indicated, replace a hydrogen on any individual ring (e.g., refers to at least .
  • an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
  • Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
  • stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
  • Suitable monovalent substituents on R ⁇ are independently halogen, -(CH2)0-2R ⁇ , - (haloR ⁇ ), -(CH2)0-2OH, -(CH2)0-2OR ⁇ , -(CH2)0-2CH(OR ⁇ )2; -O(haloR ⁇ ), -CN, -N3, -(CH2)0-2C(O)R ⁇ , - (CH2)0-2C(O)OH, -(CH2)0-2C(O)OR ⁇ , -(CH2)0-2SR ⁇ , -(CH2)0-2SH, -(CH2)0-2NH2, -(CH2)0-2NHR ⁇ , - (CH2)0-2NR ⁇ 2, -NO2, -SiR ⁇ 3, -OSiR ⁇ 3, -C(O)SR ⁇ ,
  • Suitable divalent substituents that are bound to vicinal substitutable carbons of an “optionally substituted” group include: -O(CR * 2)2-3O-, wherein each independent occurrence of R * is selected from hydrogen, C1-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Suitable substituents on the aliphatic group of R * include halogen, -R ⁇ , - (haloR ⁇ ), -OH, - OR ⁇ , -O(haloR ⁇ ), -CN, -C(O)OH, -C(O)OR ⁇ , -NH2, -NHR ⁇ , -NR ⁇ 2, or -NO2, wherein each R ⁇ is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C1-4 aliphatic, -CH2Ph, -O(CH2)0-1Ph, or a 5-6 membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Suitable substituents on a substitutable nitrogen of an “optionally substituted” group include -R ⁇ , -NR ⁇ 2, -C(O)R ⁇ , -C(O)OR ⁇ , -C(O)C(O)R ⁇ , -C(O)CH2C(O)R ⁇ , -S(O)2R ⁇ , -S(O)2NR ⁇ 2, - C(S)NR ⁇ 2, -C(NH)NR ⁇ 2, or -N(R ⁇ )S(O)2R ⁇ ; wherein each R ⁇ is independently hydrogen, C1-6 aliphatic which may be substituted as defined below, unsubstituted -OPh, or an unsubstituted 5-6- membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R ⁇ ,
  • Suitable substituents on the aliphatic group of R ⁇ are independently halogen, -R ⁇ , - (haloR ⁇ ), -OH, -OR ⁇ , -O(haloR ⁇ ), -CN, -C(O)OH, -C(O)OR ⁇ , -NH2, -NHR ⁇ , -NR ⁇ 2, or -NO2, wherein each R ⁇ is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C1-4 aliphatic, -CH2Ph, -O(CH2)0-1Ph, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference.
  • the neutral forms of the compounds are regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
  • the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention.
  • Single enantiomer refers to an enantiomeric excess of 80% or more, such as 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%.
  • Single diastereoisomer excess refers to an excess of 80% or more, for example 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99%.
  • oxo means an oxygen that is double bonded to a carbon atom, thereby forming a carbonyl.
  • the articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article.
  • an element means one element or more than one element.
  • a “dosing regimen” is a set of unit doses (typically more than one) that are administered individually to a subject, typically separated by periods of time.
  • a given therapeutic agent has a recommended dosing regimen, which may involve one or more doses.
  • a dosing regimen comprises a plurality of doses each of which are separated from one another by a time period of the same length; in some embodiments, a dosing regimen comprises a plurality of doses and at least two different time periods separating individual doses.
  • a “reference” compound is one that is sufficiently similar to a particular compound of interest to permit a relevant comparison.
  • information about a reference compound is obtained simultaneously with information about a particular compound.
  • information about a reference compound is historical.
  • information about a reference compound is stored, for example in a computer- readable medium.
  • comparison of a particular compound of interest with a reference compound establishes identity with, similarity to, or difference of the particular compound of interest relative to the compound.
  • the phrase “therapeutic agent” refers to any agent that has a therapeutic effect and/or elicits a desired biological and/or pharmacological effect, when administered to a subject.
  • the term “therapeutically effective amount” refers to an amount of a therapeutic agent that confers a therapeutic effect on the treated subject, at a reasonable benefit/risk ratio applicable to any medical treatment.
  • the therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect).
  • the “therapeutically effective amount” refers to an amount of a therapeutic agent effective to treat, ameliorate, or prevent a desired disease or condition, or to exhibit a detectable therapeutic or preventative effect, such as by ameliorating symptoms associated with the disease, preventing or delaying the onset of the disease, and/or also lessening the severity or frequency of symptoms of the disease.
  • a therapeutically effective amount is commonly administered in a dosing regimen that may comprise multiple unit doses.
  • a therapeutically effective amount (and/or an appropriate unit dose within an effective dosing regimen) may vary, for example, depending on route of administration, on combination with other pharmaceutical agents.
  • the specific therapeutically effective amount (and/or unit dose) for any particular subject may depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific therapeutic agent employed; the specific composition employed; the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and/or rate of excretion or metabolism of the specific therapeutic agent employed; the duration of the treatment; and like factors as is well known in the medical arts.
  • treatment refers to any administration of a substance (e.g., provided compositions) that partially or completely alleviates, ameliorates, relives, inhibits, delays onset of, reduces severity of, and/or reduces incidence of one or more symptoms, features, and/or causes of a particular disease, disorder, and/or condition.
  • a substance e.g., provided compositions
  • Such treatment may be of a subject who does not exhibit signs of the relevant disease, disorder and/or condition and/or of a subject who exhibits only early signs of the disease, disorder, and/or condition.
  • such treatment may be of a subject who exhibits one or more established signs of the relevant disease, disorder and/or condition.
  • treatment may be of a subject who has been diagnosed as suffering from the relevant disease, disorder, and/or condition. In some embodiments, treatment may be of a subject known to have one or more susceptibility factors that are statistically correlated with increased risk of development of the relevant disease, disorder, and/or condition.
  • a provided compound is of Formula I: or a pharmaceutically acceptable salt thereof, wherein Cy A is a phenylene or 5- to 6-membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, or a 7- to 12-membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein Cy A is substituted with 0-4 -R A groups; each R A is independently selected from oxo, halogen, -CN, -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, - S(O)R, -S(
  • Cy C is substituted with -L D -R D
  • L D is a covalent bond and R D is oxo
  • the carbon atom substituted with oxo is part of Cy C (e.g., a structure of Cy C being cyclopentyl substituted with -L D -R D at the 2-position, where L D is a covalent bond and R D is oxo corresponds to .
  • Cy A is a phenylene, wherein Cy A is substituted with 0-4 -R A groups. In some embodiments, Cy A is a phenylene, wherein Cy A is substituted with 0-2 -R A groups. [0042] In some embodiments, Cy A is a 5- to 6-membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein Cy A is substituted with 0-4 -R A groups. [0043] In some embodiments, Cy A is a 6-membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein Cy A is substituted with 0-4 -R A groups.
  • Cy A is a 6-membered monocyclic heteroarylene having 1-3 nitrogen heteroatoms, wherein Cy A is substituted with 0-4 R A groups. In some embodiments, Cy A is a pyridinediyl substituted with 0-1 R A groups. In some embodiments, Cy A is a pyrimidinediyl substituted with 0-1 R A groups. In some embodiments, Cy A is a pyridazinediyl substituted with 0-1 R A groups. In some embodiments, Cy A is a triazinediyl substituted with 0-1 R A groups. In some embodiments, Cy A is unsubstituted pyridinediyl.
  • Cy A is unsubstituted pyrimidinediyl.
  • Cy A is a 5-membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein Cy A is substituted with 0-2 -R A groups.
  • Cy A is an unsubstituted thiadiazolediyl.
  • Cy A is an unsubstituted oxadiazolediyl.
  • Cy A is an unsubstituted triazolediyl.
  • Cy A is a 7- to 12-membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein Cy A is substituted with 0-4 -R A groups.
  • Cy A is a 9-membered bicyclic heteroarylene having 3-4 heteroatoms independently selected from oxygen and nitrogen, wherein Cy A is substituted with 0-1 - R A groups.
  • Cy A is a 10-membered bicyclic heteroarylene having 3-4 heteroatoms independently selected from oxygen and nitrogen, wherein Cy A is substituted with 0-1 - R A groups.
  • Cy A is triazolopyridinediyl substituted with 0-1 -R A groups.
  • Cy A is imidazopyridinediyl substituted with 0-1 -R A groups. In some embodiments, Cy A is triazolopyrazinediyl substituted with 0-1 -R A groups. [0046] In some embodiments, Cy A is selected from the group consisting of: ( , wherein * represents point of attachment to L. [0047] In some embodiments, Cy A is selected from the group consisting of: wherein * represents the point of attachment to L. [0048] In some embodiments, Cy A is selected from the group consisting of: , wherein * represents the point of attachment to L. [0049] In some embodiments, Cy A is selected from the group consisting of: wherein * represents the point of attachment to L.
  • each R A is independently selected from oxo, halogen, -CN, - C(O) 2 R, -N(R) 2 , -OR, -SR, -S(O)R, -S(O) 2 R, or an optionally substituted group selected from C 1 - 6 aliphatic, 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, or 3- to 7- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur.
  • substituents on an optionally substituted R A group are independently halogen, -(CH 2 ) 0-4 OR ⁇ , or -(CH 2 ) 0-4 N(R ⁇ ) 2 , wherein each R ⁇ is independently as defined above and described in classes and subclasses herein.
  • a single instance of R A is oxo.
  • a single instance of R A is halogen.
  • a single instance of R A is -CN.
  • a single instance of R A is -C(O) 2 R.
  • a single instance of R A is - N(R) 2.
  • a single instance of R A is -OR. In some embodiments, a single instance of R A is -SR. In some embodiments, a single instance of R A is –SR, wherein R is optionally substituted C 1-6 aliphatic. In some embodiments, a single instance of R A is -S(O)R. In some embodiments, a single instance of R A is -S(O)R, wherein R is optionally substituted C 1-6 aliphatic. In some embodiments, a single instance of R A is -S(O) 2 R. In some embodiments, a single instance of R A is -S(O) 2 R, wherein R is optionally substituted C 1-6 aliphatic.
  • references herein to embodiments in which “a single instance” of a substituent is defined are not limited to monosubstituted embodiments.
  • a single instance of R A is oxo includes embodiments in which at least one instance of R A is oxo and which may comprise one or more additional R A groups as defined herein.
  • a single instance of R A is C 1-6 aliphatic substituted with halogen.
  • a single instance of R A is C 1-6 aliphatic substituted with -(CH 2 ) 0-4 OR ⁇ , wherein R ⁇ is selected from hydrogen or C 1-6 aliphatic.
  • a single instance of R A is C 1-6 aliphatic substituted with -(CH 2 ) 0-4 N(R ⁇ ) 2 , wherein each R ⁇ is independently selected from hydrogen or C 1-6 aliphatic.
  • a single instance of R A is optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl.
  • a single instance of R A is optionally substituted cyclopropyl.
  • a single instance of R A is optionally substituted 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur.
  • a single instance of R A is optionally substituted 3- to 7-membered saturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen and nitrogen. In some embodiments, a single instance of R A is optionally substituted oxetanyl. In some embodiments, a single instance of R A is oxetanyl optionally substituted with halogen or -(CH2)0- 4OR ⁇ . In some embodiments, a single instance of R A is pyrrolidinyl.
  • Cy B is selected from phenyl, a 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur or a 7- to 10- membered heteroaryl having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein Cy B is substituted with 0-4 -R B groups.
  • Cy B is selected from phenyl and a 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein Cy B is substituted with 0-4 -R B groups.
  • Cy B is phenyl, wherein Cy B is substituted with 0-4 -R B groups.
  • Cy B is phenyl, wherein Cy B is substituted with 0-3 -R B groups.
  • Cy B is a 6-membered heteroaryl having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein Cy B is substituted with 0-4 -R B groups.
  • Cy B is a 6-membered heteroaryl having 1-3 nitrogens, wherein Cy B is substituted with 0-4 -R B groups.
  • Cy B is a pyrimidinyl group substituted with 0-2 -R B groups.
  • Cy B is a pyridinyl group substituted with 0-2 -R B groups.
  • Cy B is a pyrazinyl group substituted with 0-1 -R B groups. In some embodiments, Cy B is a pyridazinyl group substituted with 0-1 -R B groups. In some embodiments, Cy B is a 1,3,5- triazinyl group substituted with 0-1 -R B groups. [0061] In some embodiments, Cy B is a 5-membered heteroaryl having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein Cy B is substituted with 0-4 -R B groups.
  • Cy B is a 5-membered heteroaryl having 1-2 heteroatoms independently selected from sulfur and nitrogen, wherein Cy B is substituted with 0-4 -R B groups. In some embodiments, Cy B is a thienyl group substituted with 0-2 -R B groups. In some embodiments, Cy B is a thiazolyl group substituted with 0-1 -R B groups. In some embodiments, Cy B is a thiadiazolyl group substituted with 0-1 -R B groups. [0062] In some embodiments, Cy B is selected from the group consisting of: . [0063] In some embodiments, Cy B is selected from the group consisting of: .
  • Cy B is selected from the group consisting of: .
  • each R B is independently selected from oxo, halogen, -CN, -NO2, -N(R)2, -N(R)C(O)2R, -OR, or an optionally substituted group selected from C1-6 aliphatic or a 5- membered heteroaryl having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur.
  • each R B is independently selected from halogen, -OR, or an optionally substituted 5-membered heteroaryl having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur.
  • substituents on an optionally substituted R B group are independently selected from oxo, halogen, and -(CH2)0-4OR ⁇ , wherein R ⁇ is as defined above and described in classes and subclasses herein.
  • a single instance of R B is oxo.
  • a single instance of R B is halogen.
  • a single instance of R B is fluorine.
  • a single instance of R B is chlorine.
  • a single instance of R B is - CN.
  • a single instance of R B is -NO2.
  • a single instance of R B is -N(R)2, In some embodiments, a single instance of R B is -N(R)C(O)2R. In some embodiments, a single instance of R B is -OR. In some embodiments, a single instance of R B is -OMe. [0068] In some embodiments, a single instance of R B is optionally substituted C1-6 aliphatic. In some embodiments, a single instance of R B is C1-6 aliphatic substituted with halogen.
  • a single instance of R B is -N(R)C(O)2R, wherein each R is independently selected from hydrogen or C1-6 aliphatic optionally substituted with -(CH2)0-4R ⁇ .
  • a single instance of R B is –OR, wherein each R is independently selected from hydrogen or C1-6 aliphatic optionally substituted with halogen, -(CH2)0-4OR ⁇ , or (CH2)0- 4C(O)OR ⁇ .
  • a single instance of R B is a 5-membered heteroaryl having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur.
  • L is an optionally substituted C1-3 hydrocarbon chain, wherein 1-3 methylene units are optionally replaced with -O-, -NR z -, -S-, or -SO2-. In some embodiments, L is an optionally substituted C1-3 hydrocarbon chain, wherein 1 methylene unit is optionally replaced with - O- or -NR z -. [0073] In some embodiments, L is an optionally substituted C1 hydrocarbon chain.
  • L is an optionally substituted C1 hydrocarbon chain, wherein the 1 methylene unit is replaced with 5-membered saturated or partially unsaturated heterocyclene having 1 nitrogen heteroatom, optionally substituted with -(CH2)0-4OR ⁇ , wherein R ⁇ is as defined above and described in classes and subclasses herein.
  • L is -CH2-.
  • L is optionally substituted , wherein * represents the point of attachment to Cy A .
  • L is optionally substituted , wherein * represents the point of attachment to Cy A .
  • L is optionally substituted , wherein * represents the point of attachment to Cy A .
  • L is optionally substituted , wherein * represents the point of attachment to Cy A .
  • L is , wherein * represents the point of attachment to Cy A . In some embodiments, L is , wherein * represents the point of attachment to Cy A . In some embodiments, L is , wherein * represents the point of attachment to Cy A . [0076] In some embodiments, L is an optionally substituted C2 hydrocarbon chain, wherein 1 methylene unit is optionally replaced with -NR z - or -O-. In some embodiments, L is an optionally substituted C2 hydrocarbon chain, wherein the methylene unit connected to Cy A is replaced with - NR z - or -O-.
  • L is an optionally substituted C2 hydrocarbon chain, wherein the methylene unit connected to Cy A is replaced with -NR z -. In some embodiments, L is an optionally substituted C2 hydrocarbon chain, wherein the methylene unit connected to Cy A is replaced with -O-. In some embodiments, L is *–NHCH(Me)-, wherein * represents the point of attachment to Cy A . In some embodiments, L is , wherein * represents the point of attachment to Cy A . In some embodiments, wherein * represents the point of attachment to Cy A . In some embodiments, wherein * represents the point of attachment to Cy A . In some embodiments, wherein * represents the point of attachment to Cy A . In some embodiments, H2-, wherein * represents the point of attachment to Cy A .
  • L is *–OCH(Me)-, wherein * represents the point of attachment to Cy A .
  • L is *–OCH2-, wherein * represents the point of attachment to Cy A .
  • L comprises a two-atom spacer between Cy A and . [0077] In some embodiments, L is an optionally substituted 5- to 6-membered saturated or partially unsaturated heterocyclene, having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur.
  • L is an optionally substituted 5-membered saturated or partially unsaturated heterocyclene, having 1 heteroatom independently selected from oxygen, nitrogen, and sulfur. In some embodiments, L is an optionally substituted pyrrolidinediyl group. [0078] In some embodiments, optional substituents on L are independently selected from - (CH2)0-4R ⁇ , -(CH2)0-4OR ⁇ , -(CH2)0-4OC(O)R ⁇ , and -(CH2)0-4N(R ⁇ )2, wherein each R ⁇ is independently as defined above and described in classes and subclasses herein. [0079] In some embodiments, X is -O-. In some embodiments, X is -NR y -.
  • R y is hydrogen. In some embodiments, R y is an optionally substituted C1-6 aliphatic group.
  • L’ is a covalent bond. In some embodiments, L’ is an optionally substituted C1-3 hydrocarbon chain. In some embodiments, L’ is -CH2-. In some embodiments, L’ is -CH(CH3)-. In some embodiments, L’ is wherein * represents the point of attachment to Cy B . In some embodiments, L’ is wherein * represents the point of attachment to Cy B .
  • L’ is a methylene unit optionally substituted with -(CH 2 ) 0-4 R ⁇ or -(CH 2 ) 0-4 OR ⁇ , wherein R ⁇ is independently as defined above and described in classes and subclasses herein. In some embodiments, R ⁇ is hydrogen or C 1-6 aliphatic. [0082] In certain embodiments, a carbon of L’ may optionally be taken together with R z to form a 3- to 7-membered heterocyclic ring. In certain embodiments, a carbon of L’ may optionally be taken together with R y to form a 4-membered heterocyclic ring.
  • each of R 3 , R 4 , R 5 , R 6 , and R 7 is independently selected from hydrogen or L C -R C , wherein each L C is independently selected from a covalent bond or an optionally substituted C 1-6 hydrocarbon chain, wherein 1 to 3 methylene units are optionally and independently replaced with -O- or -NR-; and wherein each R C is independently selected from halogen, -CN, - C(O)R, -C(O) 2 R, -C(O)N(R) 2 , -N(R) 2 , -N(R)C(O)R, -N(R)C(O) 2 R, -N(R)S(O) 2 R, -S(O) 2 R, -S(O) 2 R, - S(O) 2 N(R) 2 , Cy C , or an optionally substituted group selected from C 1 - 6 aliphatic.
  • R 3 is selected from hydrogen or L C -R C , wherein L C is a covalent bond and R C is halogen. In some embodiments, R 3 is hydrogen.
  • R 4 is selected from hydrogen or L C -R C , wherein L C is selected from a covalent bond or an optionally substituted C1-6 hydrocarbon chain, wherein 1 to 3 methylene units are optionally and independently replaced with -O- or -NR-; and wherein R C is selected from halogen, -CN, -C(O)R, -C(O)2R, -C(O)N(R)2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, -N(R)S(O)2R, - OR, -S(O)2R, -S(O)2N(R)2, Cy C , or an optionally substituted group selected from C1-6
  • R 4 is selected from hydrogen or L C -R C , wherein L C is a covalent bond and wherein R C is selected from halogen, -CN, -C(O)R, -C(O)2R, -C(O)N(R)2, -N(R)2, - N(R)C(O)R, -N(R)C(O)2R, -N(R)S(O)2R, -OR, -S(O)2R, -S(O)2N(R)2, Cy C , or an optionally substituted group selected from C1-6 aliphatic.
  • R 4 is hydrogen.
  • R 4 is selected from the group consisting of: .
  • optional substituents on a C 1-6 aliphatic group are selected from -(CH 2 ) 0-4 R ⁇ , -(CH 2 ) 0-4 OR ⁇ , -CN, -(CH 2 ) 0-4 N(R ⁇ ) 2 , and -(CH 2 ) 0-4 C(O)OR ⁇ , wherein each R ⁇ is independently as defined above and described in classes and subclasses herein.
  • Cy C is selected from a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur, a 5- to 6-membered monocyclic heteroaryl having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, a 6- to 12- membered saturated or partially unsaturated fused bicyclic heterocyclyl having 1-3 heteroatoms independently selected from oxygen, nitrogen, or sulfur, a bridged bicycle, or a 6- to 12- membered saturated or partially unsaturated bicyclic spiroheterocyclyl having 1-3 heteroatoms independently selected from oxygen, nitrogen, or sulfur, wherein Cy C is substituted with 0-4 -L D -R D groups.
  • Cy C is a 5- membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur.
  • Cy C is selected from the group consisting of: [0091]
  • R D is selected from oxo, halogen, -C(O)2R, -N(R)2, -OR, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl, or a 3- to 7-membered saturated or partially unsaturated monocyclic heterocyclyl having 1-2 heteroatoms selected from oxygen, nitrogen, or sulfur.
  • R D group of R 4 optional substituents on R D are selected from halogen, -(CH2)0-4R ⁇ , -(CH2)0-4OR ⁇ , -(CH2)0-4N(R ⁇ )2, -(CH2)0-4C(O)OR ⁇ , and -OP(O)(OR ⁇ )2, wherein each R ⁇ is independently as defined above and described in classes and subclasses herein.
  • L D is a covalent bond.
  • R 5 is hydrogen.
  • R 5 is L C -R C , wherein L C is a covalent bond and R C is Cy C .
  • Cy C is a cyclopropyl group.
  • R 6 is selected from hydrogen or L C -R C , wherein L C is a covalent bond, and wherein R C is selected from halogen, -N(R)2, -OR, Cy C , or an optionally substituted C1-6 aliphatic group. In some embodiments, R 6 is hydrogen.
  • Cy C is a 3- to 7-membered saturated or partially unsaturated monocyclic carbocyclyl substituted with 0-4 L D -R D groups. In some embodiments of R 6 , Cy C is a cyclopropyl group substituted with 0-4 L D -R D groups. In some embodiments, L D is a covalent bond and R D is selected from halogen and optionally substituted C1-6 aliphatic. In some embodiments of R 6 , Cy C is an unsubstituted cyclopropyl group.
  • R 7 is selected from hydrogen or L C -R C , wherein L C is a covalent bond, and wherein R C is Cy C .
  • R 7 is hydrogen.
  • Cy C is: [0101]
  • R 8 is hydrogen.
  • R 8 is selected from -OR or an optionally substituted C1-6 aliphatic group.
  • a provided compound is of Formulae II-a or II-b: II-a II-b or a pharmaceutically acceptable salt thereof, wherein each of Cy A , Cy B , L, L’, R y , R 3 , R 4 , R 5 , R 6 , and R 7 is defined and described in classes and subclasses herein, both singly and in combination.
  • a provided compound is of Formulae III-a-1, III-b-1, III-a-2, III- b-2, III-a-3, or III-b-3: or a pharmaceutically acceptable salt thereof, wherein each of Cy A , R B , L, L’, R y , R 3 , R 4 , R 5 , R 6 , and R 7 is defined and described in classes and subclasses herein, both singly and in combination.
  • a provided compound is of Formulae IV-a-1, IV-b-1, IV-a-2, or IV-b-2: IV-a-2 IV-b-2 or a pharmaceutically acceptable salt thereof, wherein each of R A , Cy B , L, L’, R y , R 3 , R 4 , R 5 , R 6 , and R 7 is defined and described in classes and subclasses herein, both singly and in combination.
  • a provided compound is of Formula V: V or a pharmaceutically acceptable salt thereof, wherein each of Cy A , Cy B , L, R 3 , R 4 , R 5 , R 6 , and R 7 is defined and described in classes and subclasses herein, both singly and in combination.
  • Cy A , Cy B , L, R 3 , R 4 , R 5 , R 6 , and R 7 is defined and described in classes and subclasses herein, both singly and in combination.
  • a provided compound is of Formulae VI-a, VI-b, or VI-c: or a pharmaceutically acceptable salt thereof, wherein each of Cy A , Cy B , X, L’, R ⁇ , R z , R 3 , R 4 , R 5 , R 6 , and R 7 is defined and described in classes and subclasses herein, both singly and in combination.
  • a provided compound is selected from the group consisting of: 3-Chlorobenzyl (6-(((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)amino)pyrimidin-4- yl)carbamate (I-1); (R)-1-(3-chlorophenyl)ethyl (6-(((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)amino)pyrimidin- 4-yl)carbamate (I-2); (S)-1-(3-chlorophenyl)ethyl (6-(((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)amino)pyrimidin- 4-yl)carbamate (I-3); 3-methoxybenzyl (6-(((6-cyclopropylimidazo[1,2-a]pyridin-2-yl)methyl)amino)amino)amino
  • compositions comprising a compound of the present disclosure, including Formulae (I)-(VI-c), or a compound of Formulae (I)-(VI-c) or an exemplified compound in combination with a pharmaceutically acceptable excipient (e.g., carrier).
  • a pharmaceutically acceptable excipient e.g., carrier
  • the pharmaceutical compositions include optical isomers, diastereomers, or pharmaceutically acceptable salts of the inhibitors disclosed herein.
  • a compound of Formulae (I)- (VI-c) included in the pharmaceutical composition may be covalently attached to a carrier moiety, as described above.
  • a compound of Formulae (I)-(VI-c) included in the pharmaceutical composition is not covalently linked to a carrier moiety.
  • a “pharmaceutically acceptable carrier,” as used herein refers to pharmaceutical excipients, for example, pharmaceutically, physiologically, acceptable organic or inorganic carrier substances suitable for enteral or parenteral application that do not deleteriously react with the active agent.
  • Suitable pharmaceutically acceptable carriers include water, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, and carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, and polyvinyl pyrrolidine.
  • Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention.
  • auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention.
  • auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention.
  • the compounds of the invention can be administered alone or can be coadministered to the subject.
  • a test agent as described herein can be incorporated into a pharmaceutical composition for administration by methods known to those skilled in the art and described herein for provided compounds.
  • D. Formulations Compounds of the present invention can be prepared and administered in a wide variety of oral, parenteral, and topical dosage forms.
  • the compounds of the present invention can be administered by injection (e.g. intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally).
  • compounds of the present disclosure are administered orally.
  • the compounds described herein can be administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally.
  • compositions comprising a pharmaceutically acceptable carrier or excipient and one or more compounds of the invention.
  • pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substance that may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from 5% to 70% of the active compound.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • preparation is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
  • a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
  • Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions.
  • liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
  • particularly suitable admixtures for the compounds of the invention are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories.
  • carriers for parenteral administration include aqueous solutions of dextrose, saline, pure water, ethanol, glycerol, propylene glycol, peanut oil, sesame oil, polyoxyethylene-block polymers, and the like. Ampoules are convenient unit dosages.
  • the compounds of the invention can also be incorporated into liposomes or administered via transdermal pumps or patches.
  • Pharmaceutical admixtures suitable for use in the present invention include those described, for example, in Pharmaceutical Sciences (17th Ed., Mack Pub. Co., Easton, PA) and WO 96/05309, the teachings of both of which are hereby incorporated by reference.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
  • viscous material such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
  • solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions.
  • the pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the quantity of active component in a unit dose preparation may be varied or adjusted according to the particular application and the potency of the active component.
  • the composition can, if desired, also contain other compatible therapeutic agents.
  • Some compounds may have limited solubility in water and therefore may require a surfactant or other appropriate co-solvent in the composition.
  • co-solvents include: Polysorbate 20, 60, and 80; Pluronic F-68, F-84, and P-103; cyclodextrin; and polyoxyl 35 castor oil.
  • co-solvents include: Polysorbate 20, 60, and 80; Pluronic F-68, F-84, and P-103; cyclodextrin; and polyoxyl 35 castor oil.
  • Such co- solvents are typically employed at a level between about 0.01 % and about 2% by weight.
  • Viscosity greater than that of simple aqueous solutions may be desirable to decrease variability in dispensing the formulations, to decrease physical separation of components of a suspension or emulsion of formulation, and/or otherwise to improve the formulation.
  • Such viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose, chondroitin sulfate and salts thereof, hyaluronic acid and salts thereof, and combinations of the foregoing.
  • Such agents are typically employed at a level between about 0.01% and about 2% by weight.
  • compositions of the present invention may additionally include components to provide sustained release and/or comfort.
  • Such components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides, and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos.4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes.
  • Effective Dosages [0134] Pharmaceutical compositions provided by the present invention include compositions wherein the active ingredient is contained in a therapeutically effective amount, i.e., in an amount effective to achieve its intended purpose.
  • compositions when administered in methods to treat HAE, such compositions will contain an amount of active ingredient effective to achieve the desired result (e.g. inhibiting PKa and/or decreasing the amount of bradykinin in a subject).
  • active ingredient effective to achieve the desired result (e.g. inhibiting PKa and/or decreasing the amount of bradykinin in a subject).
  • the dosage and frequency (single or multiple doses) of compound administered can vary depending upon a variety of factors, including route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated (e.g., the disease responsive to PKa inhibition); presence of other diseases or other health-related problems; kind of concurrent treatment; and complications from any disease or treatment regimen.
  • the therapeutically effective amount can be initially determined from cell culture assays. Target concentrations will be those concentrations of active compound(s) that are capable of decreasing PKa enzymatic activity as measured, for example, using the methods described.
  • Therapeutically effective amounts for use in humans may be determined from animal models. For example, a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals. The dosage in humans can be adjusted by monitoring PKa inhibition and adjusting the dosage upwards or downwards, as described above. [0138] Dosages may be varied depending upon the requirements of the patient and the compound being employed.
  • a compound of the disclosure or a pharmaceutical composition comprising the same is provided as a unit dose.
  • compounds provided herein display one or more improved pharmacokinetic (PK) properties (e.g., Cmax, tmax, Cmin, t1/2, AUC, CL, bioavailability, etc.) when compared to a reference compound.
  • PK pharmacokinetic
  • a reference compound is a PKa inhibitor known in the art.
  • a reference compound is a PKa inhibitor selected from those disclosed in PCT Publication Number WO 2019/178129.
  • PKa inhibitor selected from those disclosed in PCT Publication Number WO 2019/178129.
  • the present disclosure provides compounds and pharmaceutical compositions comprising the same for use in medicine, i.e., for use in treatment.
  • the present disclosure further provides the use of any compounds described herein for inhibiting the activity of PKa, which would be beneficial to treatment of PKa -mediated diseases and conditions.
  • Exemplary PKa -mediated disorders include edema, which refers to swelling in the whole body of a subject or a part thereof due to inflammation or injury when small blood vessels become leaky and releases fluid into nearby tissues.
  • the edema is HAE.
  • the edema occurs in eyes, e.g., diabetic macular edema (DME).
  • DME diabetic macular edema
  • the present disclosure provides methods of inhibiting the activity of PKa.
  • the application provides a method of inhibiting the activity of PKa in vitro via contacting any of the compounds described herein with PKa molecules in a sample, such as a biological sample.
  • the application provides a method of inhibiting the activity of PKa in vivo via delivering an effective amount of any of the compounds described herein to a subject in need of the treatment through a suitable route.
  • the methods comprise administering to a subject in need thereof (e.g., a subject such as a human patient, for example with edema) any of the compounds described herein or a pharmaceutically acceptable salt thereof.
  • the methods comprise administering a compound of Formulae (I)-(VI-c), or a pharmaceutically acceptable salt or composition thereof, to a subject in need thereof.
  • the method comprises administering a pharmaceutical composition comprising a compound of Formulae (I)-(VI-c), or a pharmaceutically acceptable salt to a subject in need thereof.
  • the subject to be treated by any of the methods described herein is a human patient having, suspected of having, or at risk for edema, for example, HAE or diabetic macular edema (DME).
  • a subject having an edema can be identified by routine medical examination, e.g., laboratory tests.
  • a subject suspected of having an edema might show one or more symptoms of the disease/disorder.
  • a subject at risk for edema can be a subject having one or more of the risk factors associated with the disease, for example, deficiency in C1-INH as for HAE.
  • provided herein are methods of alleviating one or more symptoms of HAE in a human patient who is suffering from an HAE attack.
  • Such a patient can be identified by routine medical procedures.
  • An effective amount of one or more of the provided compounds can be given to the human patient via a suitable route, for example, those described herein.
  • the compounds described herein may be used alone, or may be used in combination with other anti-HAE agents, for example, a C1 esterase inhibitor (e.g., Cinryze ® or Berinert ® ), a PKa inhibitor (e.g., ecallantide or lanadelumab) or a bradykinin B2 receptor antagonist (e.g., Firazyr ® ).
  • a C1 esterase inhibitor e.g., Cinryze ® or Berinert ®
  • PKa inhibitor e.g., ecallantide or lanadelumab
  • a bradykinin B2 receptor antagonist e.g., Firazyr ®
  • provided herein are methods or reducing the risk of HAE attack in a human HAE patient who is in qui
  • Such a patient can be identified based on various factors, including history of HAE attack.
  • An effective amount of one or more of the compounds can be given to the human patient via a suitable route, for example, those described herein.
  • the compounds described herein may be used alone, or may be used in combination with other anti-HAE agents, for example, a C1 esterase inhibitor (e.g., Cinryze ® or Berinert ® ), a PKa inhibitor (e.g., ecallantide or lanadelumab) or a bradykinin B2 receptor antagonist (e.g., Firazyr ® ).
  • a C1 esterase inhibitor e.g., Cinryze ® or Berinert ®
  • PKa inhibitor e.g., ecallantide or lanadelumab
  • a bradykinin B2 receptor antagonist e.g., Firazyr ®
  • prophylactic treatment of HAE in human patients having risk to HAE attacks with one or more of the compounds described herein are human subjects suffering from HAE (e.g., having history of HAE attacks).
  • patients suitable for such prophylactic treatment are human subjects where a physician determines a history of HAE attacks warrants a prophylactic approach (e.g., human subjects experiencing more than a particular average number of attacks over a time period, including by way of nonlimiting example, one, two, or more attacks per month).
  • patients suitable for the prophylactic treatment may be human subjects having no HAE attack history but bearing one or more risk factors for HAE (e.g., family history, genetic defects in C1-INH gene, etc.)
  • prophylactic treatment may involve the compounds described herein as the sole active agent, or involve additional anti-HAE agents, such as those described herein.
  • methods for preventing or reducing edema in an eye of a subject e.g., a human patient.
  • the human patient is a diabetic having, suspected of having, or at risk for diabetic macular edema (DME).
  • DME diabetic macular edema
  • DME is the proliferative form of diabetic retinopathy characterized by swelling of the retinal layers, neovascularization, vascular leak, and retinal thickening in diabetes mellitus due to leaking of fluid from blood vessels within the macula.
  • an effective amount of one or more of the compounds described herein, or pharmaceutically acceptable salts thereof may be delivered into the eye of the subject where treatment is needed.
  • the compound may be delivered topically, by intraocular injection, or intravitreal injection.
  • a subject may be treated with the compound as described herein, either as the sole active agent, or in combination with another treatment for DME.
  • Non-limiting examples of treatment for DME include laser photocoagulation, steroids, VEGF pathway targeting agents (e.g., Lucentis® (ranibizumab) or Eylea ® (aflibercept)), and/or anti-PDGF agents.
  • the methods disclosed herein comprise administering to the subject an effective amount of a compound of Formulae (I)-(VI-c), or a pharmaceutically acceptable salt or composition thereof.
  • the effective amount is a therapeutically effective amount.
  • the effective amount is a prophylactically effective amount.
  • the subject being treated is an animal. The animal may be of either sex and may be at any stage of development.
  • the subject is a mammal. In certain embodiments, the subject being treated is a human. In certain embodiments, the subject is a domesticated animal, such as a dog, cat, cow, pig, horse, sheep, or goat. In certain embodiments, the subject is a companion animal, such as a dog or cat. In certain embodiments, the subject is a livestock animal, such as a cow, pig, horse, sheep, or goat. In certain embodiments, the subject is a zoo animal. In another embodiment, the subject is a research animal such as a rodent (e.g., mouse, rat), dog, pig, or non-human primate. In certain embodiments, the animal is a genetically engineered animal.
  • the animal is a transgenic animal.
  • Certain methods described herein may comprise administering one or more additional pharmaceutical agent(s) in combination with the compounds described herein.
  • the additional pharmaceutical agent(s) may be administered at the same time as the compound of Formulae (I)-(VI- c), or at different times than the compound of Formulae (I)-(VI-c).
  • the compound of Formulae (I)-(VI-c) and any additional pharmaceutical agent(s) may be on the same dosing schedule or different dosing schedules.
  • All or some doses of the compound of Formulae (I)-(VI-c) may be administered before all or some doses of an additional pharmaceutical agent, after all or some does an additional pharmaceutical agent, within a dosing schedule of an additional pharmaceutical agent, or a combination thereof.
  • the timing of administration of the compound of Formulae (I)-(VI-c) and additional pharmaceutical agents may be different for different additional pharmaceutical agents.
  • the additional pharmaceutical agent comprises an agent useful in the treatment of an edema, such as HAE or DME. Examples of such agents are provided herein.
  • Also provided is used of a compound of the present disclosure for the manufacture of a medicament for a condition/disease disclosed herein.
  • the resulting suspension was degassed for 10 min and Pd(OAc)2 (0.65 g, 2.9 mmol) was added.
  • the reaction mixture was stirred at 95 °C for 16 h under N2 atmosphere.
  • the mixture was cooled to room temperature, diluted with water (30 mL), and extracted with ethyl acetate (3 ⁇ 30 mL).
  • the organic phase was washed with brine (150 mL), passed through a hydrophobic frit, and concentrated in vacuo.
  • the residue was purified by silica gel chromatography, eluting with a gradient of 10-95 % EtOAc in hexane to give the title compound (5.3 g, 68 %) as a red solid.
  • reaction mixture was stirred at 80 o C for 2 h under nitrogen.
  • the reaction mixture was filtered through Celite ® and the filter cake was washed with DCM/MeOH (10/1, 20 mL).
  • the filtrate was concentrated in vacuo to give the crude, which was purified by column chromatography on silica gel, eluting with 20-100% EA/PE to afford (4-chloropyridin-2-yl)methyl (6-((2R,4S)-4-((tert- butyldimethylsilyl)oxy)-2-(6-cyclopropylimidazo[1,2-a]pyridin-2-yl)pyrrolidin-1-yl)pyrimidin-4- yl)carbamate (80 mg, 44%) as a yellow solid.
  • Compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide substrate.
  • concentrations of reagents were as follows: 20 mM Tris pH 7.5, 1 mM EDTA, 150 mM sodium chloride, 0.1% PEG-400, 0.1% Triton X-100, 500 pM activated kallikrein enzyme, 300 uM Pro-Phe- Arg-7-amido-4-methylcoumarin (PFR-AMC) substrate. Prior to reaction initiation with substrate, enzyme and inhibitors were preincubated for 30 min at room temperature.
  • reaction initiation with substrate After initiation with substrate, reactions were incubated for 10 min at room temperature and fluorescence emission at 460 nm from 380 nm excitation measured with a microplate reader.
  • concentrations of reagents were as follows: 20 mM Tris pH 7.5, 1 mM EDTA, 150 mM sodium chloride, 0.1% PEG-400, 0.1% Triton X-100, 5 pM activated kallikrein enzyme, 300 uM PFR-AMC substrate. Prior to reaction initiation with substrate, enzyme and inhibitors were preincubated for 30 min at room temperature.
  • Table 2 provides the results of the assay in the format with 500 pM activated kallikrein assay.
  • the EC50 values are reported according to the following ranges: A ⁇ 5.0 nM; 5.0 nM ⁇ B ⁇ 50 nM; 50 nM ⁇ C ⁇ 500 nM; 500 nM ⁇ D ⁇ 9000 nM; 9000 nM ⁇ E.
  • Example 36 Neat human and rat plasma assay [0276] To analyze inhibition of plasma kallikrein in an ex vivo setting, the potency of compounds was measure in contact pathway-activated plasma assays. In a fluorogenic peptide substrate assay, test compounds dissolved in DMSO were added to sodium citrate collected human or rat plasma in a 96-well microplate. Alternatively, citrated plasma was collected from rats administered the compounds orally or by IV.
  • a compound of Formula I I or a pharmaceutically acceptable salt thereof, wherein Cy A is a phenylene or 5- to 6-membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, or a 7- to 12-membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein Cy A is substituted with 0-4 -R A groups; each R A is independently selected from oxo, halogen, -CN, -C(O)R, -C(O)2R, -C(O)N(R)2, -NO2, -N(R)2, -N(R)C(O)R, -N(R)C(O)2R, -N(R)S(O)2R, -OR, -OC(O)R, -OC(O)N(R)2, -SR, - S(O)R, -
  • Cy A is a 5- to 6-membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein Cy A is substituted with 0-4 -R A groups.
  • Cy A is a 6-membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein Cy A is substituted with 0-4 -R A groups.
  • Cy A is selected from the group consisting of: , wherein * represents the point of attachment to L. 5.
  • Cy A is a pyridinediyl substituted with 0-1 R A groups. 6.
  • Cy A is a pyrimidinediyl substituted with 0-1 R A groups.
  • Cy A is a 7- to 12-membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein Cy A is substituted with 0-4 -R A groups.
  • Cy A is triazolopyridinediyl, imidazopyridinediyl, or triazolopyrazinediyl, wherein Cy A is substituted with 0-1 -R A groups.
  • Cy B is selected from phenyl and a 5- to 6-membered heteroaryl having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein Cy B is substituted with 0-4 -R B groups. 10. The compound of any one of the preceding embodiments, wherein Cy B is phenyl, wherein Cy B is substituted with 0-3 -R B groups. 11. The compound of any one embodiments 1-9, wherein Cy B is a 6-membered heteroaryl having 1-3 nitrogens, wherein Cy B is substituted with 0-4 -R B groups. 12.
  • Cy B is a pyrimidinyl group substituted with 0-2 -R B groups. In some embodiments, Cy B is a pyridinyl group substituted with 0-2 -R B groups. 13. The compound of any one of the preceding embodiments, wherein Cy B is selected from the group consisting of: . 14. The compound of any one of the preceding embodiments, wherein each R B is independently selected from halogen, -OR, or an optionally substituted group selected from C1-6 aliphatic or a 5-membered heteroaryl having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur. 15.
  • L is an optionally substituted 5- membered saturated or partially unsaturated heterocyclene, having 1 heteroatom independently selected from oxygen, nitrogen, and sulfur. In some embodiments, L is an optionally substituted pyrrolidinediyl group. 23. The compound of any one of embodiments 1-14 or 22, wherein L is , wherein * represents the point of attachment to Cy A . 24. The compound of any one of the preceding embodiments, wherein L comprises a two-atom spacer between Cy A and 25. The compound of any one of the preceding embodiments, wherein X is -O-. 26. The compound of any one of the preceding embodiments, wherein X is -NR y -. 27.
  • R 3 is hydrogen.
  • R 4 is hydrogen 38.
  • R 5 is hydrogen.
  • R 6 is selected from hydrogen or L C -R C , wherein L C is a covalent bond, and wherein R C is selected from halogen, -N(R) 2 , -OR, Cy C , or an optionally substituted C 1-6 aliphatic group. 40.
  • the method of embodiment 54, wherein the disease or disorder is hereditary angioedema.
  • 56. The method of embodiment 54, wherein the disease or disorder is diabetic macular edema.
  • 57. A method of treating hereditary angioedema comprising administering to a patient in need thereof a compound or composition of any one of the preceding embodiments.
  • 58. A method of treating diabetic macular edema comprising administering to a patient in need thereof a compound or composition of any one of the preceding embodiments. 59.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés et des compositions de ceux-ci qui sont utiles en tant qu'inhibiteurs de la kallicréine plasmatique et qui présentent des caractéristiques souhaitables pour ceux-ci.
EP22714692.5A 2021-03-17 2022-03-16 Inhibiteurs imidazopyridinyle de la kallicréine plasmatique Pending EP4308227A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163162494P 2021-03-17 2021-03-17
PCT/US2022/020474 WO2022197755A1 (fr) 2021-03-17 2022-03-16 Inhibiteurs imidazopyridinyle de la kallicréine plasmatique

Publications (1)

Publication Number Publication Date
EP4308227A1 true EP4308227A1 (fr) 2024-01-24

Family

ID=81325446

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22714692.5A Pending EP4308227A1 (fr) 2021-03-17 2022-03-16 Inhibiteurs imidazopyridinyle de la kallicréine plasmatique

Country Status (4)

Country Link
EP (1) EP4308227A1 (fr)
JP (1) JP2024510502A (fr)
CN (1) CN117396473A (fr)
WO (1) WO2022197755A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022549601A (ja) 2019-09-18 2022-11-28 武田薬品工業株式会社 ヘテロアリール血漿カリクレインインヒビター
FI4031547T3 (fi) 2019-09-18 2024-09-16 Takeda Pharmaceutical Company Ltd Plasman kallikreiinin estäjiä ja niiden käyttötapoja

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (fr) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Utilisation de carragheenane dans des compositions ophthalmologiques topiques
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
EP2430013B1 (fr) * 2009-05-13 2014-10-15 Amgen Inc. Composés heteraryles comme inhibiteurs de la pikk
AU2019234670B2 (en) 2018-03-13 2023-11-23 Takeda Pharmaceutical Company Limited Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof

Also Published As

Publication number Publication date
WO2022197755A1 (fr) 2022-09-22
JP2024510502A (ja) 2024-03-07
CN117396473A (zh) 2024-01-12

Similar Documents

Publication Publication Date Title
EP3500569B1 (fr) 2-oxo-imidazopyridines en tant qu'inhibiteurs réversibles de btk et leurs utilisations
TWI557127B (zh) 布魯頓氏酪胺酸激酶抑制劑
EP4031547B1 (fr) Inhibiteurs de la kallicréine plasmatique et leurs utilisations
CA3093802A1 (fr) Imidazopyridines substituees en tant qu'inhibiteurs de la kallicreine plasmatique et leurs utilisations
BR112020005934A2 (pt) inibidor de pde9 e uso do mesmo
WO2017071516A1 (fr) Inhibiteur de kinase et procédé pour sa préparation et utilisation pharmaceutique correspondante
US11370803B2 (en) Heteroaryl plasma kallikrein inhibitors
EP4308227A1 (fr) Inhibiteurs imidazopyridinyle de la kallicréine plasmatique
AU2016215184A1 (en) Pyridazinone macrocycles as IRAK inhibitors and uses thereof
CA3056426A1 (fr) Composes de quinolinyle et utilisation comme antagonistes du recepteur de kappa-opioide et produits et methodes connexes
EP4308564A1 (fr) Inhibiteurs polycycliques de kallicréine plasmatique
US20180118718A1 (en) Substituted Quinoxaline Derivatives
JP7451569B2 (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾールホモフタルイミド誘導体化合物、およびそれを含む薬剤学的組成物
CN117396469A (zh) 血浆激肽释放酶的抑制剂
CN108341819B (zh) 磷酸二酯酶抑制剂及其用途
WO2022233442A1 (fr) Dérivés de 2,8-dihydropyrazolo[3,4-b]indole destinés à être utilisés dans le traitement du cancer
TW200526642A (en) Heterocyclic derivatives
KR20230022861A (ko) Tead 결합제로서 유용한 트리시클릭 헤테로사이클
US20240199612A1 (en) Imidazopyridinyl inhibitors of plasma kallikrein
WO2024214038A1 (fr) Antagonistes du récepteur du polypeptide insulinotrope dépendant du glucose et leurs utilisations
WO2024145505A1 (fr) Composés de pyrimidine carboxamide
WO2022217070A1 (fr) Composés mimétiques de hgf/sf
AU2021444255A1 (en) 2,8-dihydropyrazolo[3,4-b]indole derivatives for use in the treatment of cancer
TW202237101A (zh) Ｃｔｌａ－４小分子降解劑及其應用
NL1026091C2 (nl) PDE9-remmers voor de behandeling van type 2 diabetes, metabolisch syndroom en cardiovasculaire ziekte.

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230928

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40106238

Country of ref document: HK